jRCT1030260181招募中不适用
Clinical Performance Testing Using the Fully Automated Genetic Testing Device GENECUBE and Respiratory Pathogen Genetic Detection Reagents in Respiratory Specimens
未提供0 个研究点目标入组 1,000 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Patients presenting with suspected respiratory infection who have new consented specimens or residual/stored specimens such as postnasal, nasopharyngeal, pharyngeal swabs, or sputum.
排除标准
- •When consent is withdrawn
- •When a request to refuse secondary use is made for stored specimens originating from other studies
- •When no residual specimens remain
研究者
相似试验
招募中
不适用
Clinical Performance Study: Detection of Sexually Transmitted Infection related pathogens using GENECUBE and dedicated detection reagents in various clinical specimensInfectious diseasesjRCT10302601801,000
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
已完成
1 期
This is clinical study to test, for the first time in people, the safety (any
good or bad effects), how long the drug can stay in the body and if it can
control the disease of people diagnosed with advanced cancer that has not
responded to treatment, has returned after it has been treated, or cannot
be treated by surgery, drugs, or any other known treatments.2023-509969-20-00Celgene Corp.127
尚未招募
不适用
Evaluation of the Efficacy, Safety, and Patient Self-Assessment in Reducing Downtime by Use of Membrane Formation Collagen Hydrogel Following Ablative CO2 Fractional Laser ResurfacingN/A, healthy people.jRCT10702501175
招募中
2 期
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment2024-518069-89-00Centr Georges Francois Leclerc230